Methylation levels of CADM1, MAL, and MIR124-2 in cervical scrapes for triage of HIV-infected, high-risk HPV-positive women in Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 3, 2015, Pages 311-318

  De Vuyst, Hugo ^a   Franceschi, Silvia ^a   Plummer, Martyn ^a   Mugo, Nelly R ^b   Sakr, Samah R ^c   Meijer, Chris J L M ^d   Heideman, Daniëlle A M ^d   Tenet, Vanessa ^a   Snijders, Peter J F ^d   Hesselink, Albertus T ^d   Chung, Michael H ^e  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c Internal Medicine and Critical care Department   (Kenya)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cervical intraepithelial neoplasia; Human papillomavirus; Methylation; Screening; Triage

Indexed keywords

ACETIC ACID; CELL ADHESION MOLECULE; MATURATION ASSOCIATED PROTEIN; MICRORNA; MICRORNA124 2; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CADM1 PROTEIN, HUMAN; IMMUNOGLOBULIN; MAL PROTEIN, HUMAN; MIRN124 MICRORNA, HUMAN; MYELIN AND LYMPHOCYTE PROTEIN; VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; DNA METHYLATION; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KENYA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; COMPLICATION; EMERGENCY HEALTH SERVICE; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; METABOLISM; METHYLATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVIX; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BIOMARKERS; CELL ADHESION MOLECULES; CERVIX UTERI; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS; KENYA; METHYLATION; MICRORNAS; MYELIN AND LYMPHOCYTE-ASSOCIATED PROTEOLIPID PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TRIAGE;

EID: 84944453134     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000744     Document Type: Article

References (38)

1. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents. Lyon, France: International Agency for Research on Cancer; 2012.
2. Chung MH, McKenzie KP, De Vuyst H, et al. Comparing papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy. AIDS. 2013;27:2909-2919.
3. Kuhn L, Wang C, Tsai WY, et al. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS. 2010;24:2553-2561.
4. Joshi S, Sankaranarayanan R, Muwonge R, et al. Screening of cervical neoplasia in HIV-infected women in India. AIDS. 2013;27:607-615.
5. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 (suppl 10):K29-K41.
6. De Vuyst H, Mugo NR, Chung MH, et al. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer. 2012;107:1624-1630.
7. Giorgi-Rossi P, Franceschi S, Ronco G. HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer. 2012;130:1387-1394.
8. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol. 2013;25:11-16.
9. Dijkstra MG, van ND, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev. 2014; 23:55-63.
10. WHO. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva, Switzerland: WHO; 2013.
11. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
12. Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112:293-299.
13. Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn. 2014;14:293-305.
14. Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395-405.
15. Overmeer RM, Henken FE, Snijders PJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008;215:388-397.
16. Overmeer RM, Henken FE, Bierkens M, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol. 2009;219:327-336.
17. Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.
18. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res. 2011;17:2459-2465.
19. Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2013;133:1293-1299.
20. Hesselink AT, Heideman DA, Steenbergen RD, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer. 2014;135:880-886.
21. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15: 315-322.
22. Nye MD, Hoyo C, Huang Z, et al. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS One. 2013;8:e56325.
23. Vidal AC, Henry NM, Murphy SK, et al. PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. Clin Transl Oncol. 2014;16: 266-272.
24. Chung MH, McKenzie KP, Richardson BA, et al. Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3. AIDS. 2011;25:1915-1919.
25. Luff RD. The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda workshop. Am J Clin Pathol. 1992;98:152-154.
26. De Vuyst H, Mugo NR, Franceschi S, et al. Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia Grade 2/3 in HIV-positive women in Kenya. PLoS One. 2014;9:e111037.
27. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000;87:221-227.
28. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779-787.
29. Canty A, Ripley B. Boot: Bootstrap R (S-Plus) Functions. [Software]. (R Package Version 1.3-9). 2013. Available at: http://CRAN.R-project.org/package=boot. Accessed 25 September 2013.
30. Mendenhall W, Wackerly DD, Scheaffer RL. Nonparametric statistics. In: Mathematical Statistics With Applications. 4th ed. Boston, MA: PWS-Kent; 1989:674-679.
31. Belisle CJP. Convergence theorems for a class of simulated annealing algorithms on Rd. J Appl Prob. 1992;29:885-895.
32. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
33. Clifford GM, Goncalves MA, Franceschi S, et al. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20: 2337-2344.
34. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349-2359.
35. De Vuyst H, Ndirangu G, Moodley M, et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer. 2012;131:949-955.
36. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-1772.
37. Snellenberg S, De Strooper LM, Hesselink AT, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer. 2012;12:551.
38. Gravitt PE, Rositch AF. HPV self-testing and cervical cancer screening coverage. Lancet Oncol. 2014;15:128-129.